We are live on ! Find out more
VBIV

VBI Vaccines, Inc. New Common Stock (Canada)
VBIV

Delisted

VBIV was delisted on the 7th of August, 2024.

Back to rankings

46 hedge funds and large institutions have $7.06M invested in VBI Vaccines, Inc. New Common Stock (Canada) in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 11 increasing their positions, 24 reducing their positions, and 50 closing their positions.

New
Increased
Maintained
Reduced
Closed

8,833% more call options, than puts

Call options by funds: $536K | Put options by funds: $6K

52% less funds holding

Funds holding: 95 → 46 (-49)

54% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 24

75% less capital invested

Capital invested by funds: $27.9M → $7.06M (-$20.8M)

96% less first-time investments, than exits

New positions opened: 2 | Existing positions closed: 50

Holders
46
Holders Change
-49
Holders Change %
-51.58%
% of All Funds
0.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
11
Reduced
24
Closed
50
Calls
$536K
Puts
$6K
Net Calls
+$530K
Net Calls Change
+$457K

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$268K
2
Morgan Stanley
Morgan Stanley
New York
+$206K
3
YIH
Y-Intercept (HK)
Hong Kong
+$120K
4
Jane Street
Jane Street
New York
+$34.7K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$18K

Top Sellers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
-$1.1M
2
BlackRock
BlackRock
New York
-$949K
3
State Street
State Street
Massachusetts
-$304K
4
Renaissance Technologies
Renaissance Technologies
New York
-$242K
5
Bank of New York Mellon
Bank of New York Mellon
New York
-$215K

VBIV Hedge Fund Activity: Q2 2023 in Review

46 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) for Q2 2023, worth a combined $7.06M — down 75% from $27.9M a quarter earlier.

Sellers outnumbered buyers: 50 funds closed out of VBIV and 2 opened new positions — a net loss of 48 holders — while 24 trimmed existing stakes and 11 added.

The largest buyer was Millennium Management, adding an estimated $268K. The largest seller was Perceptive Advisors, cutting an estimated $1.1M.

  • 46 institutional investors held VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) as of Q2 2023, down from 95 in Q1 2023.
  • Funds reported $7.06M of VBI Vaccines, Inc. New Common Stock (Canada) stock for Q2 2023, down 75% quarter-over-quarter.
  • 2 funds opened new VBI Vaccines, Inc. New Common Stock (Canada) positions in Q2 2023 and 50 closed out, a net change of -48 holders.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) buyer in Q2 2023 was Millennium Management, an estimated $268K added.
  • The largest VBI Vaccines, Inc. New Common Stock (Canada) seller in Q2 2023 was Perceptive Advisors, an estimated $1.1M sold.

Based on aggregated 13F filings for Q2 2023.